Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2004-11-10 (21 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: DOUAI (59500), Nord
SARL PHARMACIE LINGLART : revenue, balance sheet and financial ratios
SARL PHARMACIE LINGLART is a French company
founded 21 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in DOUAI (59500),
this company of category PME
shows in 2023 a revenue of 1.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SARL PHARMACIE LINGLART (SIREN 479447997)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
1 436 658 €
N/C
N/C
N/C
N/C
1 300 159 €
1 141 904 €
Net income
54 109 €
33 263 €
64 726 €
131 617 €
60 930 €
43 566 €
83 922 €
34 670 €
74 403 €
EBITDA
N/C
N/C
80 980 €
N/C
N/C
N/C
N/C
56 523 €
114 460 €
Net margin
N/C
N/C
4.5%
N/C
N/C
N/C
N/C
2.7%
6.5%
Revenue and income statement
In 2025, SARL PHARMACIE LINGLART generates positive net income of 54 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 74 k€ -> 54 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
54 109 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 17%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 71%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
17.066%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
70.671%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
57.999
80.083
55.816
47.963
43.259
30.533
23.131
22.842
17.066
Financial autonomy
53.381
46.517
53.175
54.407
57.755
63.372
67.586
68.953
70.671
Repayment capacity
4.065
12.549
None
None
None
None
3.024
None
None
Cash flow / Revenue
6.613%
2.739%
None%
None%
None%
None%
4.241%
None%
None%
Sector positioning
Debt ratio
17.072025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of SARL PHARMACIE LINGLART (17.07) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
70.67%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of SARL PHARMACIE LINGLART (70.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
3.02 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of SARL PHARMACIE LINGLART (3.02) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 47.92. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
62.863
81.979
56.482
49.224
64.378
79.57
68.939
57.115
47.925
Interest coverage
12.7
28.028
None
None
None
None
3.81
None
None
Sector positioning
Liquidity ratio
47.922025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch
In 2025, the liquidity ratio of SARL PHARMACIE LINGLART (47.92) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
3.81x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of SARL PHARMACIE LINGLART (3.8x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 26 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 996 days. Excellent situation: suppliers finance 970 days of the operating cycle (retail model).
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
26 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
996 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SARL PHARMACIE LINGLART
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
80 424 €
130 133 €
0 €
0 €
0 €
0 €
90 280 €
0 €
0 €
Inventory turnover (days)
25
27
0
0
0
0
20
0
0
Customer payment term (days)
3
6
0
59
41
51
1
26
26
Supplier payment term (days)
54
54
0
1331
976
971
53
839
996
Positioning of SARL PHARMACIE LINGLART in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SARL PHARMACIE LINGLART is estimated at
859 527 €
(range 583 279€ - 1 348 717€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
583k€859k€1348k€
859 527 €Range: 583 279€ - 1 348 717€
NAF 5 année 2025
Valuation method used
Net Income Multiple
54 109 €
×
15.9x
=859 528 €
Range: 583 280€ - 1 348 718€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SARL PHARMACIE LINGLART with other companies in the same sector:
Frequently asked questions about SARL PHARMACIE LINGLART
What is the revenue of SARL PHARMACIE LINGLART ?
The revenue of SARL PHARMACIE LINGLART in 2023 is 1.4 M€.
Is SARL PHARMACIE LINGLART profitable?
Yes, SARL PHARMACIE LINGLART generated a net profit of 54 k€ in 2025.
Where is the headquarters of SARL PHARMACIE LINGLART ?
The headquarters of SARL PHARMACIE LINGLART is located in DOUAI (59500), in the department Nord.
Where to find the tax return of SARL PHARMACIE LINGLART ?
The tax return of SARL PHARMACIE LINGLART is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SARL PHARMACIE LINGLART operate?
SARL PHARMACIE LINGLART operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart